The glucose sensor crossed a boundary: benefit without insulin therapy

October 14, 2026 online; October 29 journal issue · Randomized multicenter effectiveness trial; older online result revisited · Primary source

Continuous glucose monitoring began as a tool for people who depended on insulin. A major U.S. primary-care trial published online October 14 suggests a wider role: an unobtrusive source of feedback for adults with type 2 diabetes who were not using insulin. This is older than our 24-hour news window, and it has been brought forward for its clinical importance, not mislabeled as an overnight discovery.

At 22 primary-care practices, 145 adults were assigned to continuous monitoring and 138 to routine care over 26 weeks. HbA1c fell from 8.8% to 7.2% with CGM and from 8.7% to 8.0% in controls: an adjusted between-group difference of −0.9 percentage points (95% CI −1.1 to −0.6). CGM users also spent 21 percentage points more time in the 70–180 mg/dL range (95% CI 16–26). No severe hypoglycemia occurred. The study was funded by Dexcom.

The practical question is what enabled the improvement: feedback, behavior changes, clinician attention, treatment adjustments, or some combination. We cannot attribute the effect to a specific mechanism without additional analysis. Nor does a better six-month glucose profile alone establish reduced cardiovascular events. But this RCT shows a potentially meaningful short-term disease-control benefit in an everyday primary-care setting.

Clinical reading: A practice-relevant trial for discussing CGM with appropriate non–insulin-treated adults; coverage and individualized management require current review.